ABPO · Abpro Holdings, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, based on the considerations discussed above, management has concluded there is substantial doubt as to the Company's ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | — | $183K | $122K | — | |
| $373K | $989K | $2.98M | $4.27M | — | |
| $4.97M | $7.46M | $7.12M | $7.6M | — | |
| $12K | $21K | $74K | $279K | — | |
| $1.18M | $8.45M | $10.1M | $11.87M | — | |
| -$5.34M | -$8.45M | -$9.92M | -$11.75M | -$2.05M | |
| — | — | -5421.31% | -9627.87% | — | |
| -$5.33M | -$8.43M | -$9.85M | -$11.47M | — | |
| — | $1.13M | $387K | $23K | — | |
| $70K | $33K | $9000 | $63K | — | |
| $7.35M | $5.56M | $2.69M | $40K | $3.76M | |
| — | — | -$7.23M | -$11.71M | $1.71M | |
| $141.78K | — | — | $1.18M | $823.99K | |
| $2.01M | -$2.89M | -$7.23M | $2.82M | $886.92K | |
| — | — | -3951.91% | 2312.67% | — | |
| USD/shares | $2.16 | -$1.30 | -$22.31 | -$18.30 | — |
| USD/shares | $2.16 | -$1.30 | -$22.31 | -$18.30 | — |
| shares | — | 2.23M | 780.33K | 637.78K | — |
| shares | — | 2.23M | 780.33K | 637.78K | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2023: $276.47M in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Unsecured debt, including current maturities | 2026-01-31 | USD 147,000 | 10-Q filed 2026-08-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 144 similar-size Biotechnology companies (of 560 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2024 | FY2023 |
|---|---|---|
| Research and Development Services | $183,000 | — |
| Collaboration Revenue | — | $99,000 |
| Royalty | — | $23,000 |